Ignite Creation Date:
2024-07-17 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06469281
Status:
RECRUITING
Last Update Posted:
2024-06-21
First Post:
2024-06-06
Brief Title:
A Study to Learn if 27T51 a Mucin-16 MUC16 Protein Targeting Immune Cell Therapy Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Sponsor:
Regeneron Pharmaceuticals
Organization:
Regeneron Pharmaceuticals